Table 1 Characteristics of studies included in analysis.
From: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis
Authors and year of publication | Study type | Number of participants | Range of ages (years) | Route of administ-ration | Intervention and control | Indication | Follow up period | Funding |
|---|---|---|---|---|---|---|---|---|
Dalzell et al.49 | RCT. double blind, crossover | 23a | 0.8–17.0 | Oral capsules or white powder | Nabilone vs. domperidone | Chemotherapy-Induced Emesis | Two cycles of chemotherapyb | Eli Lilly |
Chan et al.48 | RCT, double-blind, crossover | 36a | 3.5–17.8 | Oral capsules | Nabilone vs. prochlorperazine | Chemotherapy-Induced Emesis | Two cycles of chemotherapyb | Eli Lilly |
Devinsky et al.28 | RCT, double-blind | 120 | 2.3–18.4 | Oral solution | CBD 20 mg/kg/d vs. Placebo | Dravet syndrome | 14-week treatment period, a 10-day taper period, and a 4-week safety follow-up period | GW Pharmaceuticals |
Devinsky et al.30 | RCT, double-blind | 34 | 4.0–10.9 | Oral solution | CBD 5,10,20 mg/kg/d vs. Placebo | Dravet syndrome | 3-week treatment, 10-day taper, and 4-week safety follow-up periods | GW Pharmaceuticals |
Miller et al.50 | RCT, double-blind | 199 | 2.0–18.0 | Oral solution | CBD dose 10,20 mg/kg/d vs. Placebo | Dravet syndrome | 2-week titration period followed by a 12-week maintenance period | GW Pharmaceuticals |
Fairhurst et al.51 | RCT, double-blind | 72 | 8.0–18.0 | Spray | max 12 actuations of Nabiximols sprayc vs. Placebo | Spasticity due to cerebral palsy or traumatic, non‐progressive CNS injury | Patients titrated over a period of 9 weeks followed by 3 weeks of maintenance to a total of 12 weeks | GW Pharmaceuticals |
Efron et al.52 | RCT, double-blind | 8 | 8.0–16.0 | Oral solution | CBD 20 mg/kg/d vs. Placebo | Severe behavioral problems with intellectual disability | 9-days up-titration, followed by 8 weeks of maintenance and 9 days down-titration | Internal grant (not commercial sponsor) |
Aran et al53 | RCT, double-blind, crossover | 150 | 5–21 | Oral solution | whole-plant cannabis extract, purified CBD and THC vs. Placebod | Autism spectrum disorder | 12-weeks, followed by a 4-week washout and cross-over for another 12 weeks | BOL Pharma and the National Institute for Psychobiology in Israel |
